OCGN NASDAQ
Ocugen, Inc.
1W: +0.0%
1M: -22.7%
3M: -31.5%
YTD: -26.1%
1Y: -39.3%
3Y: +150.8%
5Y: -86.5%
$1.02
+0.02 (+2.00%)
Weekly Expected Move ±12.1%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
19 relationships16
As Filer
counterparties named
3
As Counterparty
mentioned by others
5
Rel. Types
2021-06-07
Earliest Filing
2025-09-18
Latest Filing
partner: 8
licensee: 2
target: 2
acquirer: 2
investor: 2
Counterparties (Filed by OCGN)
16 relationshipsCompanies named in OCGN's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Kwangdong Pharmaceutical Co., Ltd. | — | licensee | Granted an exclusive, non-sublicensable license to import, export, distribute, and commercialize Ocugen's OCU400 gene th | 2025-09-16 | View |
| OrthoCellix, Inc. | — | target | Wholly-owned subsidiary of Ocugen entered into a Merger Agreement to merge with Merger Sub. | 2025-09-05 | View |
| Carisma Therapeutics Inc. | CARM | acquirer | Agreed to acquire OrthoCellix and receive a $5.0 million concurrent investment from Ocugen. | 2025-09-05 | View |
| OrthoCellix, Inc. | — | target | Wholly-owned subsidiary of Ocugen that merged into Carisma | 2025-06-23 | View |
| Carisma Therapeutics Inc. | CARM | acquirer | Delaware corporation that acquired OrthoCellix in a merger | 2025-06-23 | View |
| Azalea Merger Sub, Inc. | — | partner | Wholly owned subsidiary of Carisma used as the merger vehicle | 2025-06-23 | View |
| ModernaTX, Inc. | MRNA | partner | Counterparty to Carisma's existing collaboration and license agreement | 2025-06-23 | View |
| Titan Partners Group LLC | KMCM | investor | Underwriter for the public offering of common stock | 2024-08-01 | View |
| American Capital Partners, LLC | AIG | investor | Parent entity of the underwriter Titan Partners Group LLC | 2024-08-01 | View |
| The Washington University | — | licensee | Ocugen entered into an exclusive license agreement for intranasal COVID-19 vaccine patent rights. | 2022-09-28 | View |
| Cantor Fitzgerald & Co. | — | partner | Sales agent in at-market issuance agreement | 2022-06-10 | View |
| H.C. Wainwright & Co., LLC | — | partner | Sales agent in at-market issuance agreement | 2022-06-10 | View |
| Roth Capital Partners, LLC | — | partner | Sales agent in at-market issuance agreement | 2022-06-10 | View |
| Chardan Capital Markets, LLC | — | partner | Sales agent in at-market issuance agreement | 2022-06-10 | View |
| Bharat Biotech International Limited | — | partner | Co-Development, Supply and Commercialization Agreement for COVAXIN vaccine rights | 2022-04-18 | View |
| Bharat Biotech International Limited | — | partner | Co-Development, Supply and Commercialization Agreement for COVAXIN vaccine rights | 2021-06-07 | View |
Mentioned As Counterparty
3 mentionsOther companies that named OCGN in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| CARM Carisma Therapeutics Inc. | acquirer | Target of terminated Merger Agreement and investor in subscription agreement | 2025-09-18 | View |
| CARM Carisma Therapeutics Inc. | investor | Agreed to purchase $5.0 million of common stock in a private placement as part of the Concurrent Investment. | 2025-08-29 | View |
| CARM Carisma Therapeutics Inc. | acquirer | Target company in the merger agreement with Carisma Therapeutics Inc. | 2025-06-23 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-23 | Shareholder Vote | View | |
| 2026-09-08 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-07-13 | Other Events; Exhibits | View | |
| 2026-06-11 | Shareholder Vote; Other Events | View | |
| 2026-06-03 | Officer/Director Change | View | |
| 2026-05-14 | Officer/Director Change; Other Events | View | |
| 2026-05-14 | Financial Obligation; Unregistered Equity Sales; Regulation FD; Exhibits | View | |
| 2026-05-07 | Material Agreement; Termination of Agreement; Earnings Release; Financial Obligation; Unregistered E | Agreement | View |
| 2026-05-05 | Earnings Release; Other Events; Exhibits | View | |
| 2026-05-04 | Earnings Release; Regulation FD; Other Events; Exhibits | View | |
| 2026-03-27 | Regulation FD; Exhibits | View | |
| 2026-03-24 | Regulation FD; Exhibits | View | |
| 2026-03-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-03-04 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-09 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-01-23 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2026-01-21 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2026-01-15 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-18 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR